Prognosis and survival evaluation in treating high-risk BRAF V600 mutation stage III or IV melanoma with dabrafenib plus trametinib therapy: A meta-analysis of 2,660 patients.

Authors: Arturo Ortiz, Aldo Ascencio, Diego Pichardo Rojas, Nancy E. Arreola Sevilla, William B. Olivos Zegarra, Eva L. Valadez Montero, Alfonso Alvarez Castro, Leslie I. Morales Alvarez, Jose Ramon Flores Valdes, Jaqueline Livier Castillo, Jorge E. Cortes, Brenda Santellano

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e21501

Source: Full article

---

Abstract

e21501